TCR2 Therapeutics Inc.
TCRR · NASDAQ
12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|
| Market Cap | $39 | $177 | $866 | $301 |
| - Cash | $33 | $223 | $94 | $65 |
| + Debt | $54 | $26 | $0 | $0 |
| Enterprise Value | $60 | -$19 | $772 | $236 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$90 | -$97 | -$67 | -$51 |
| % Margin | – | – | – | – |
| Net Income | -$152 | -$100 | -$67 | -$48 |
| % Margin | – | – | – | – |
| EPS Diluted | -3.93 | -2.63 | -2.4 | -2.26 |
| % Growth | -49.4% | -9.6% | -6.2% | – |
| Operating Cash Flow | -$101 | -$82 | -$57 | -$41 |
| Capital Expenditures | -$15 | -$11 | -$7 | -$4 |
| Free Cash Flow | -$117 | -$93 | -$64 | -$45 |